The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer

European Urology

Volumn 55, Issue 4, 2009, Pages 815-825

  Stenzl, Arnulf ^a   Cowan, Nigel C ^b   De Santis, Maria ^c   Jakse, Gerhard ^d   Kuczyk, Marcus A ^e   Merseburger, Axel S ^e   Ribal, Maria José ^f   Sherif, Amir ^g   Witjes, J Alfred ^h  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^d UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f UNIVERSITY OF BARCELONA   (Spain)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bladder neoplasms; Chemotherapy; Cystectomy; Guidelines; Muscle invasive bladder cancer; Urinary diversion

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; METHOTREXATE; PACLITAXEL; VINBLASTINE;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; COMPUTER ASSISTED TOMOGRAPHY; CYSTECTOMY; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TRANSURETHRAL RESECTION;

FEMALE; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; URINARY BLADDER NEOPLASMS;

EID: 60249099004     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.01.002     Document Type: Review

References (93)

1. Oosterlinck W., Lobel B., Jakse G., Malmström P.-U., Stöckle M., Sternberg C., and The EAU Working Group on Oncological Urology. Guidelines on bladder cancer. Eur Urol 41 (2002) 105-112
2. Centre for Evidence-Based Medicine. Levels of evidence. http://www.cebm.net/index.aspx?o=1025. Accessed October 24, 2008.
3. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
4. Kogevinas M., Mannetje A., Cordier S., et al. Occupation and bladder cancer among men in Western Europe. Cancer Causes Control 14 (2003) 907-914
5. Chrouser K., Leibovich B., Bergstralh E., Zincke H., and Blute M. Bladder cancer risk following primary and adjuvant external beam radiation for prostate cancer. J Urol 174 (2005) 107-110 discussion 110-1
6. Boorjian S., Cowan J.E., Konety B.R., et al. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol 177 (2007) 883-887 discussion 887-8
7. Vaidya A., Soloway M.S., Hawke C., Tiguert R., and Civantos F. De novo muscle invasive bladder cancer: is there a change in trend?. J Urol 165 (2001) 47-50 discussion 50
8. McGrath M., Michaud D.S., and De Vivo I. Hormonal and reproductive factors and the risk of bladder cancer in women. Am J Epidemiol 163 (2006) 236-244
9. Sobin DH, Wittekind Ch, eds. TNM Classification of Malignant Tumours. 6th ed. New York, NY: Wiley-Liss; 2002. p. 199-202.
10. Sauter G., Algaba F., Amin M., et al. Tumours of the urinary system: non-invasive urothelial neoplasias. In: Eble J.N., Sauter G., Epstein Jl, and Sesterhenn I. (Eds). World Health Organization Classification of Tumors: Pathology and Genetics of the Urinary System and Male Genital Organs (2004), IARCC Press, Lyon, France 29-34
11. Jimenez R.E., Gheiler E., Oskanian P., et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol 24 (2000) 980-987
12. Fossa S.D., Ous S., and Berner A. Clinical significance of the "palpable mass" in patients with muscle-infiltrating bladder cancer undergoing cystectomy after preoperative radiotherapy. Br J Urol 67 (1991) 54-60
13. Paik M.L., Scolieri M.J., Brown S.L., and Resnick M.I. Limitations of computed tomography in the preoperative staging of upper tract urothelial carcinoma. Urology 56 (2000) 930-934
14. Van Der Molen A.J., Cowan N.C., Mueller-Lisse U.G., Nolte-Ernsting C.C., Takahashi S., and Cohan R.H. CT urography: definition, indications and techniques. A guideline for clinical practice. Eur Radiol 18 (2008) 4-17
15. Holmang S., Hedelin H., Anderstrom C., Holmberg E., and Johansson S.L. Long-term follow-up of a bladder carcinoma cohort: routine follow-up urography is not necessary. J Urol 160 (1998) 45-48
16. Palou J., Rodriguez-Rubio F., Huguet J., et al. Multivariate analysis of clinical parameters of synchronous primary superficial bladder cancer and upper urinary tract tumor. J Urol 174 (2005) 859-861 discussion 861
17. Nolte-Ernsting C., and Cowan N. Understanding multislice CT urography techniques: many roads lead to Rome. Eur Radiol 16 (2006) 2670-2686
18. Raitanen M.-P., Aine R., Rintala E., et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol 41 (2002) 284-289
19. Lokeshwar V.B., Habuchi T., Grossman H.B., et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66 Suppl 1 (2005) 35-63
20. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
21. Stenzl A., Colleselli K., and Bartsch G. Update of urethra-sparing approaches in cystectomy in women. World J Urol 15 (1997) 134-138
22. Heidenreich A., Aus G., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 53 (2008) 68-80
23. Damiano R., Di Lorenzo G., Cantiello F., et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 52 (2007) 648-657
24. Mallampati G.K., and Siegelman E.S. MR imaging of the bladder. Magn Reson Imaging Clin N Am 12 (2004) 545-555 vii
25. Kim J.K., Park S.Y., Ahn H.J., Kim C.S., and Cho K.S. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 231 (2004) 725-731
26. Kundra V., and Silverman P.M. Imaging in oncology from the University of Texas M.D. Anderson Cancer Center. Imaging in the diagnosis, staging, and follow-up of cancer of the urinary bladder. AJR Am J Roentgenol 180 (2003) 1045-1054
27. Jager G.J., Barentsz J.O., Oosterhof G.O., Witjes J.A., and Ruijs S.J. Pelvic adenopathy in prostatic and urinary bladder carcinoma: MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence. AJR Am J Roentgenol 167 (1996) 1503-1507
28. Barentsz J.O., Engelbrecht M.R., Witjes J.A., de la Rosette J.J., and van der Graaf M. MR imaging of the male pelvis. Eur Radiol 9 (1999) 1722-1736
29. Cowan N.C., Turney B.W., Taylor N.J., McCarthy C.L., and Crew J.P. Multidetector computed tomography urography for diagnosing upper urinary tract urothelial tumour. BJU Int 99 (2007) 1363-1370
30. Dorfman R.E., Alpern M.B., Gross B.H., and Sandler M.A. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology 180 (1991) 319-322
31. Lauenstein T.C., Goehde S.C., Herborn C.U., et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology 233 (2004) 139-148
32. Schmidt G.P., Schoenberg S.O., Reiser M.F., and Baur-Melnyk A. Whole-body MR imaging of bone marrow. Eur J Radiol 55 (2005) 33-40
33. Sternberg C.N., Pansadoro V., Calabro F., et al. Can patient selection for bladder preservation be based on response to chemotherapy?. Cancer 97 (2003) 1644-1652
34. Sanchez-Ortiz R.F., Huang W.C., Mick R., Van Arsdalen K.N., Wein A.J., and Malkowicz S.B. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J Urol 169 (2003) 110-115 discussion 115
35. Stein J.P. Contemporary concepts of radical cystectomy and the treatment of bladder cancer. J Urol 169 (2003) 116-117
36. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003) 859-866
37. Vale C.A., and Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data. Eur Urol 48 (2005) 189-201 discussion 199-201
38. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet 1999; 354:533-40.
39. Sherif A., Holmberg L., Rintala E., et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol 45 (2004) 297-303
40. Sternberg C.N., de Mulder P.H., Schornagel J.H., et al., European Organization for Research, Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol 19 (2001) 2638-2646
41. Herr H.W., Bajorin D.F., and Scher H.I. Neoadjuvant chemotherapy and bladder-sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol 16 (1998) 1298-1301
42. Hautmann R.E., Abol-Enein H., Hafez K., et al. Urinary diversion. Urology 69 Suppl (2007) 17-49
43. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666-675
44. Miller D.C., Taub D.A., Dunn R.L., Montie J.E., and Wei J.T. The impact of comorbid disease on cancer control and survival following radical cystectomy. J Urol 169 (2003) 105-109
45. Hautmann R.E., and Paiss T. Does the option of the ileal neobladder stimulate patient and physician decision toward earlier cystectomy?. J Urol 159 (1998) 1845-1850
46. Stenzl A., Nagele U., Kuczyk M., et al. Cystectomy: technical considerations in male and female patients. EAU Update Series 3 (2005) 138-146
47. Vallancien G., Abou El Fettouh H., Cathelineau X., Baumert H., Fromont G., and Guillonneau B. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 168 (2002) 2413-2417
48. Muto G., Bardari F., D'Urso L., and Giona C. Seminal sparing cystectomy and ileocapsuloplasty: long-term follow-up results. J Urol 172 (2004) 76-80
49. Abdelhady M., Abusamra A., Pautler S.E., Chin J.L., and Izawa J.I. Clinically significant prostate cancer found incidentally in radical cystoprostatectomy specimens. BJU Int 99 (2007) 326-329
50. Pettus J.A., Al-Ahmadie H., Barocas D.A., et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol 53 (2008) 370-375
51. Weizer A.Z., Shah R.B., Lee C.T., et al. Evaluation of the prostate peripheral zone/capsule in patients undergoing radical cystoprostatectomy: defining risk with prostate capsule sparing cystectomy. Urol Oncol 25 (2007) 460-464
52. Herr H.W., Bochner B.H., Dalbagni G., Donat S.M., Reuter V.E., and Bajorin D.F. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J Urol 167 (2002) 1295-1298
53. Leissner J., Hohenfellner R., Thuroff J.W., and Wolf H.K. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis. BJU Int 85 (2000) 817-823
54. Poulsen A.L., Horn T., and Steven K. Radical cystectomy: extending the limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall. J Urol 160 (1998) 2015-2019 discussion 2020
55. Ghoneim M.A., and Abol-Enein H. Lymphadenectomy with cystectomy: is it necessary and what is its extent?. Eur Urol 46 (2004) 457-461
56. Fleischmann A., Thalmann G.N., Markwalder R., and Studer U.E. Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol 23 (2005) 2358-2365
57. Schumacher M.C., Scholz M., Weise E.S., Fleischmann A., Thalmann G.N., and Studer U.E. Is there an indication for frozen section examination of the ureteral margins during cystectomy for transitional cell carcinoma of the bladder?. J Urol 176 (2006) 2409-2413 discussion 2413
58. Stenzl A. Bladder substitution. Curr Opin Urol 9 (1999) 241-245
59. Tanrikut C., and McDougal W.S. Acid-base and electrolyte disorders after urinary diversion. World J Urol 22 (2004) 168-171
60. Farnham S.B., and Cookson M.S. Surgical complications of urinary diversion. World J Urol 22 (2004) 157-167
61. Hautmann R.E., Volkmer B.G., Schumacher M.C., Gschwend J.E., and Studer U.E. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol 24 (2006) 305-314
62. Gschwend J.E., Dahm P., and Fair W.R. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy. Eur Urol 41 (2002) 440-448
63. Hollenbeck B.K., Miller D.C., Taub D., et al. Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology 64 (2004) 292-297
64. Figueroa A.J., Stein J.P., Dickinson M., et al. Radical cystectomy for elderly patients with bladder carcinoma: an updated experience with 404 patients. Cancer 83 (1998) 141-147
65. Widmark A., Flodgren P., Damber J.E., Hellsten S., and Cavallin-Stahl E. A systematic overview of radiation therapy effects in urinary bladder cancer. Acta Oncol 42 (2003) 567-581
66. Ubrig B., Lazica M., Waldner M., and Roth S. Extraperitoneal bilateral cutaneous ureterostomy with midline stoma for palliation of pelvic cancer. Urology 63 (2004) 973-975
67. Rodel C., Grabenbauer G.G., Kuhn R., et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol 20 (2002) 3061-3071
68. Zietman A.L., Grocela J., Zehr E., et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology 58 (2001) 380-385
69. Shipley W.U., Kaufman D.S., Zehr E., et al. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 60 (2002) 62-67 discussion 67-8
70. Herr H.W. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol 19 (2001) 89-93
71. Sternberg C.N. Perioperative chemotherapy in muscle-invasive bladder cancer to enhance survival and/or as a strategy for bladder preservation. Semin Oncol 34 (2007) 122-128
72. Freiha F., Reese J., and Torti F.M. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 155 (1996) 495-499 discussion 499-500
73. Stockle M., Meyenburg W., Wellek S., et al. Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol 153 (1995) 47-52
74. Studer U.E., Bacchi M., Biedermann C., et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 152 (1994) 81-84
75. Skinner D.G., Daniels J.R., Russell C.A., et al. Adjuvant chemotherapy following cystectomy benefits patients with deeply invasive bladder cancer. Semin Urol 8 (1990) 279-284
76. Sylvester R., and Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol 11 (2000) 851-856
77. Bajorin D.F., Dodd P.M., Mazumdar M., et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17 (1999) 3173-3181
78. von der Maase H., Sengelov L., Roberts J.T., et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23 (2005) 4602-4608
79. Sternberg C.N., Yagoda A., Scher H.I., et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64 (1989) 2448-2458
80. Logothetis C.J., Dexeus F.H., Finn L., et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8 (1990) 1050-1055
81. Sternberg C.N., de Mulder P., Schornagel J.H., et al., EORTC Genito-Urinary Cancer Group. Seven-year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 42 (2006) 50-54
82. Stadler W.M., Hayden A., von der Maase H., et al. Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer. Urol Oncol 7 (2002) 153-157
83. Hussain M., Vaishampayan U., Du W., Redman B., and Smith D.C. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 19 (2001) 2527-2533
84. Malkowicz S.B., van Poppel H., Mickisch G., et al. Muscle-invasive urothelial carcinoma of the bladder. Urology 69 Suppl 1 (2007) 3-16
85. Bochner B.H., Montie J.E., and Lee C.T. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 30 (2003) 777-789
86. Sanderson K.M., Cai J., Miranda G., Skinner D.G., and Stein J.P. Upper tract urothelial recurrence following radical cystectomy for transitional cell carcinoma of the bladder: an analysis of 1,069 patients with 10-year follow-up. J Urol 177 (2007) 2088-2094
87. Freeman J.A., Tarter T.A., Esrig D., et al. Urethral recurrence in patients with orthotopic ileal neobladders. J Urol 156 (1996) 1615-1619
88. Levinson A.K., Johnson D.E., and Wishnow K.I. Indications for urethrectomy in an era of continent urinary diversion. J Urol 144 (1990) 73-75
89. Stenzl A., Draxl H., Posch B., Colleselli K., Falk M., and Bartsch G. The risk of urethral tumors in female bladder cancer: can the urethra be used for orthotopic reconstruction of the lower urinary tract?. J Urol 153 (1995) 950-955
90. Nieder A.M., Sved P.D., Gomez P., Kim S.S., Manoharan M., and Soloway M.S. Urethral recurrence after cystoprostatectomy: implications for urinary diversion and monitoring. Urology 64 (2004) 950-954
91. Varol C., Thalmann G.N., Burkhard F.C., and Studer U.E. Treatment of urethral recurrence following radical cystectomy and ileal bladder substitution. J Urol 172 (2004) 937-942
92. Clark P.E., Stein J.P., Groshen S.G., et al. The management of urethral transitional cell carcinoma after radical cystectomy for invasive bladder cancer. J Urol 172 (2004) 1342-1347
93. Lin D.W., Herr H.W., and Dalbagni G. Value of urethral wash cytology in the retained male urethra after radical cystoprostatectomy. J Urol 169 (2003) 961-963